Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Fritz C. Eilber, M.D.
Fritz C. Eilber, M.D.

General Information:



Associate Professor, Department of Surgery
Physician, Department of Surgery, Surgical Oncology, Gastrointestinal Surgery, Melanoma, UCLA Sarcoma Program
Member, JCCC Cancer Molecular Imaging Program Area


Surgical Oncology, Memorial Sloan-Kettering Cancer Center, 2002 - 2004
General Surgery, UCLA School of Medicine, 1996 - 2002
General Surgery, UCLA School of Medicine, 1995 - 1996
Medical Degree:
M.D., UCLA School of Medicine, 1995


Board Certification(s):
Surgery, American Board of Surgery, 2003

Contact Information:

(310) 825-7086
(310) 825-7086 Surgical Oncology office and Information
(310) 206-6909 Surgical Oncology new patients and referrals
(310) 206-6931 Surgical Oncology follow-up appointments
(310) 825-2644 Surgical Oncology referring physician
(310) 825-7086 Sarcoma Program information and referral

Practice Information:

Clinical Interest(s):
Colon Cancer
Gastric Cancer
Gastrointestinal Malignancies
General Surgical Oncology
Solid Tumors

Scientific Interest(s):

Dr. Fritz C. Eilber’s research is focused on translating molecular oncology from the laboratory to the clinic in a rapid and clinically relevant manner with the goal of swiftly impacting patient care. His long-term objective is to rationally apply molecularly targeted therapies in the context of defined genetic lesions thus developing effective and individualized therapeutic strategies for patients with sarcoma and other solid tumors. He has recently focused on applying molecular imaging to evaluate response to systemic therapy (traditional chemotherapy, targeted therapy) and direct regional therapies (surgery, radiation therapy, embolization) in solid tumors.

Selected Cancer-Related Publications:

Benz MR, Czernin J, Allen-Auerbach MS, Dry SM, Sutthiruangwong P, Spick C, Radu C, Weber WA, Tap WD, Eilber FC. 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response. Cancer. 2012 Jun 15;118(12):3135-44. Epub 2011 Oct 21

Herrmann K, Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Schuster T, Eckardt JJ, Phelps ME, Weber WA, Eilber FC. 18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy. Clin Cancer Res. 2012 Apr 1;18(7):2024-31. Epub 2012 Feb 14

Tap WD, Eilber FC, Ginther C, Dry SM, Reese N, Barzan-Smith K, Chen HW, Wu H, Eilber FR, Slamon DJ, Anderson L. Evaluation of well-differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization. Genes Chromosomes Cancer. 2011 Feb;50(2):95-112.

Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Elashoff D, Chow K, Evilevitch V, Eckardt JJ, Phelps ME, Weber WA, Eilber FC. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res. 2009 Apr 15;15(8):2856-63. Epub 2009 Apr 7

Gregorian C, Nakashima J, Dry SM, Nghiemphu PL, Smith KB, Ao Y, Dang J, Lawson G, Mellinghoff IK, Mischel PS, Phelps M, Parada LF, Liu X, Sofroniew MV, Eilber FC, Wu H. PTEN dosage is essential for neurofibroma development and malignant transformation. Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19479-84. Epub 2009 Oct 21